Brief: Quince Therapeutics Regains Compliance With Nasdaq Listing Rule
14/11/2024 12:17
Nov 14 (Reuters) - Quince Therapeutics Inc QNCX.O :
* QUINCE THERAPEUTICS: REGAINS COMPLIANCE WITH NASDAQ
LISTING RULE
5450(A)(1)
Source text: https://tinyurl.com/5ntrewxs
Further company coverage: QNCX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IRulya Therapeutics
See all newsBrief: Quince Therapeutics - Changes Name To Irulya Therapeutics
Brief: Quince Therapeutics - Appoints Brigette Roberts As CEO Effective October 8, 2026
Quince Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Quince Therapeutics Reports Second Quarter 2026 Financial Results And Corporate Update
Quince Therapeutics Q2 net loss widens on acquisition charges